In vivo vitiligo induction and therapy model: Double-blind, randomized clinical trial

Pigment Cell and Melanoma Research

Volumn 25, Issue 1, 2012, Pages 57-65

  van Geel, Nanja ^a   Speeckaert, Reinhart ^a   Mollet, Ilse ^a   de Schepper, Sofie ^a   de Wolf, Julie ^a   Tjin, Esther P M ^b   Luiten, Rosalie M ^b   Lambert, Jo ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Experimental model; Koebner phenomenon; Topical immunomodulators; Treatment; Vitiligo

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS; PLACEBO; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRYOTHERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; IN VIVO STUDY; LOW LEVEL LASER THERAPY; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SKIN ABRASION; T LYMPHOCYTE; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADULT; CRYOTHERAPY; DERMABRASION; DOUBLE-BLIND METHOD; FEMALE; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LANGERHANS CELLS; LASER THERAPY, LOW-LEVEL; MALE; MART-1 ANTIGEN; MIDDLE AGED; OINTMENTS; PREGNADIENEDIOLS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTE SUBSETS; TACROLIMUS; TRIAMCINOLONE ACETONIDE; VITILIGO;

EID: 83955164180     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00922.x     Document Type: Article

References (19)

1. Ahmed, M., Venkataraman, R., Logar, A.J., Rao, A.S., Bartley, G.P., Robert, K., Dodson, F.S., Shapiro, R., Fung, J.J., and Zeevi, A. (2001). Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther. Drug Monit. 23, 354-362.
2. Bilgiç, O., Bilgiç, A., Akiş, H.K., Eskioǧlu, F., and Kiliç, E.Z. (2011). Depression, anxiety and health-related quality of life in children and adolescents with vitiligo. Clin. Exp. Dermatol. 36, 360-365.
3. van den Boorn, J.G., Konijnenberg, D., Dellemijn, T.A., van der Veen, J.P., Bos, J.D., Melief, C.J., Vyth-Dreese, F.A., and Luiten, R.M. (2009). Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129, 2220-2232.
4. Choi, C.W., Chang, S.E., Bak, H. et al. (2008). Topical immunomodulators are effective for treatment of vitiligo. J. Dermatol. 35, 503-507.
5. Clark, R.A., Chong, B.F., Mirchandani, N., Yamanaka, K., Murphy, G.F., Dowgiert, R.K., and Kupper, T.S. (2006). A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol 126, 1059-1070.
6. Gauthier, Y. (1995). The importance of Koebner's phenomenon in the induction of vitiligo vulgaris lesions. Eur J Dermatol 5, 704-708.
7. Gauthier, Y., Cario Andre, M., and Taïeb, A. (2003). A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?. Pigment Cell Res. 16, 322-332.
8. Gawkrodger, D.J., Ormerod, A.D., Shaw, L. et al. (2008). Guideline for the diagnosis and management of vitiligo. Br. J. Dermatol. 159, 1051-1076.
9. van Geel, N., Speeckaert, R., Taieb, A. et al. (2011). Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 24, 564-573.
10. Jin, Y., Birlea, S.A., Fain, P.R. et al. (2011). Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol 131, 1308-1312.
11. Kostopoulou, P., Jouary, T., Quintard, B., Ezzedine, K., Marques, S., Boutchnei, S., and Taïeb, A. (2009). Objective versus subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br. J. Dermatol. 161, 128-133.
12. Kumar, R., Parsad, D., and Kanwar, A.J. (2011). Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br. J. Dermatol. 164, 187-191.
13. Lane, C., Leitch, J., Tan, X., Hadjati, J., Bramson, J.L., and Wan, Y. (2004). Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 64, 1509-1514.
14. Lee, D.J., and Modlin, R.L. (2005). Breaking tolerance-another piece added to the vitiligo puzzle. J Invest Dermatol 124, 13-15.
15. Lotti, T., Buggiani, G., Troiano, M., Assad, G.B., Delescluse, J., De Giorgi, V., and Hercogova, J. (2008). Tageted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol. Ther. 21, S20-S26.
16. Mandelcorn-Monson, R.L., Shear, N.H., Yau, E., Sambhara, S., Barber, B.H., Spaner, D., and DeBendedette, M.A. (2003). Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 121, 550-556.
17. Paul, W.E., and Seder, R.A. (1994). Lymphocyte responses and cytokines. Cell 76, 241-251.
18. Sweet, R.D. (1978). Vitiligo as a Köbner phenomenon. Br. J. Dermatol. 99, 223-224.
19. Whitton, M.E., Pinart, M., Batchelor, J., Lushey, C., Leonardi-Bee, J., and Gonzàlez, U. (2010). Interventions for vitiligo. Cochrane Database Syst Rev 20, CD003263.